Fabry's disease: Difference between revisions

	Fabry's disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fabry's disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Fabry's disease On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fabry's disease All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fabry's disease
CDC on Fabry's disease
Fabry's disease in the news
Blogs on Fabry's disease
Directions to Hospitals Treating Fabry's disease
Risk calculators and risk factors for Fabry's disease

← Older edit

VisualWikitext

Latest revision as of 20:07, 23 May 2022

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Differentiating Fabry's disease from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Treatment

Case Studies

Case #1

External links

Fabry Support & Information Group
Template:NINDS
Fabry's disease at NLM Genetics Home Reference
Fabry's Disease Association

References

[1] Caterina Bartolotta, Marcello Filogamo, Paolo Colomba, Carmela Zizzo, Giuseppe Albeggiani, Simone Scalia, Daniele Francofonte, Giuseppe Cammarata, Vincenzo Savica, Giovanni Duro, FP907 HISTORY OF ANDERSON - FABRY DISEASE, Nephrology Dialysis Transplantation, Volume 30, Issue suppl_3, 1 May 2015, Page iii379, https://doi.org/10.1093/ndt/gfv186.08

[2] Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8: 539–548.

[3] Elleder M, Poupĕtová H, Kozich V . Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I. Cesk Patol 1998;34:7–12.

[4] Thurberg BL, Politei JM . Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. Hum Pathol 2012;43:610–614. [5] Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M; European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006 Apr;43(4):347-52. Epub 2005 Oct 14. Citation on PubMed or Free article on PubMed Central

@@ Line 15: / Line 15: @@
    MeshID         = D000795 |
 }}
-{{CMG}};{{AE}} {{AN}}
+{{Fabry's disease}}
+{{CMG}}; {{AE}}
-{{SK}} Anderson-Fabry disease; angiokeratoma corporis diffusum universale; alpha-glucosidase A deficiency; ceramide trihexosidase deficiency; hereditary dystopic lipidosis; GLA deficiency; Sweeley-Klionsky disease
-==Overview==
+==[[Fabry's disease overview|Overview]]  ==
-'''Fabry disease''' is an [[X-linked recessive]] inherited [[lysosomal storage disease]], characterized by abnormal accumulation of ceramide trihexose in cardiovascular and renal systems.
-==Historical Perspective==
+*
-It is named for Johannes Fabry.<ref>{{WhoNamedIt|synd|1761}}</ref>
+*
-==Classification==
+==[[Fabry's disease historical perspective|Historical Perspective]]==
-*Non-neuropathic form
-*Neuropathic form
-**Infantile form
-**Juvenile form
-==Pathophysiology==
+==[[Fabry's disease classification|Classification]]==
-*Fabry's disease follows an X-linked recessive inheritance pattern.
-*A deficiency of the [[enzyme]] [[alpha galactosidase|alpha galactosidase A]] causes a [[glycolipid]] known as globotriaosylceramide (also abbreviated as Gb3, GL-3, or ceramide trihexoside) to accumulate within the [[blood vessel]]s, mononuclear phagocytes, neurons, other tissues, and organs.
-*This accumulation leads to an impairment of their proper function. The condition affects [[Zygosity|hemizygous]] males, as well as both [[Zygosity|heterozygous]] and [[Zygosity|homozygous]] females; males tend to experience the most severe clinical symptoms, while females vary from virtually no symptoms to those as serious as males.
-*This variability is thought to be due to [[X-inactivation]] patterns during embryonic development of the female.
-==Epidemiology and Demographics==
+==[[Fabry's disease pathophysiology|Pathophysiology]]==
-The prevalence of Fabry disease is estimated to range from 1:17,000 to 1:117,000 males in Caucasian populations.<ref name="pmid11889412">{{cite journal |author=Branton MH, Schiffmann R, Sabnis SG, ''et al.'' |title=Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course |journal=[[Medicine]] |volume=81 |issue=2 |pages=122–38 |year=2002 |month=March |pmid=11889412 |doi= |url=}}</ref><ref name="pmid9918480">{{cite journal |author=Meikle PJ, Hopwood JJ, Clague AE, Carey WF |title=Prevalence of lysosomal storage disorders |journal=[[JAMA : the Journal of the American Medical Association]] |volume=281 |issue=3 |pages=249–54 |year=1999 |month=January |pmid=9918480 |doi= |url=}}</ref>
+==[[Fabry's disease causes|Causes]]==
+==[[Fabry's disease differential diagnosis|Differentiating Fabry's disease from other Diseases]]==
+==[[Fabry's disease epidemiology and demographics|Epidemiology and Demographics]]==
+==[[Fabry's disease risk factors|Risk Factors]]==
+==[[Fabry's disease screening|Screening]]==
+==[[Fabry's disease natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
 ==Diagnosis==
-===Symptoms===
-*Lack of sweating ([[anhidrosis]]) or decreased sweating
-*[[fatigue (medical)|Fatigue]]
-*Red spots on skin ([[angiokeratoma]]s): tiny, painless [[papules]] that appear at any region of the body, but are predominant on the thighs, buttocks, lower abdomen, and groin.
-*Burning pain of the extremities. This pain can become very intense, especially when one has a fever.
-*[[Loss of vision]] or blurry vision from corneal opacities.
-*[[Abdominal pain]]
-*[[Chest pain]] and [[palpitations]]
-*[[Delayed puberty]]
-*[[Pyrexia of unknown origin]]
-*[[cyanosis]] of extremities on exposure to cold ([[Raynaud's phenomenon]])
-*[[Hearing loss]]
-*[[Loss of sensations]] in extremities
-*[[Telangiectasis]]
 ==Treatment==
-Until recently, treatment of Fabry disease targeted the [[symptomatic]] effects.  However, it is currently being treated at the cellular level through enzyme replacement therapy using [[Agalsidase alpha]] (Replagal) and [[Agalsidase beta]] (Fabrazyme®).  The cost of these drugs is problematic (approximately $170,000 US a year/patient) and remains a barrier to many patients in some countries. Enzyme replacement therapy (typically infused every two weeks) may be performed in the patient's home by the patients themselves. Enzyme replacement therapy is not a cure, and must be infused recurrently for maximum benefit.
-==References==
+[[Fabry's disease medical therapy|Medical Therapy]] | [[Fabry's disease surgery|Surgery]] | [[Fabry's disease primary prevention|Primary Prevention]] | [[Fabry's disease secondary prevention|Secondary Prevention]] | [[Fabry's disease cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Fabry's disease future or investigational therapies|Future or Investigation Therapies]]
-{{reflist|2}}
+==Case Studies==
+[[Fabry's disease case study one|Case #1]]
 ==External links==
-* [http://www.genzyme.com/]
 * [http://www.fabry.org/FSIG.nsf/Pages2/HomePage Fabry Support & Information Group]
-* [http://www.fabrycommunity.com/global/fc_p_hp_homepage.asp Fabry Community (Information, Causes, & Treatment - Est. by [[Genzyme Corporation]])]
-* [http://www.fabrycanada.com Canadian Fabry Association]
 * {{NINDS|fabrys}}
 * {{NLM|fabrydisease}}
 * [http://www.apmf-fabry.org/ Fabry's Disease Association]
+== References ==
+[1] Caterina Bartolotta, Marcello Filogamo, Paolo Colomba, Carmela Zizzo, Giuseppe Albeggiani, Simone Scalia, Daniele Francofonte, Giuseppe Cammarata, Vincenzo Savica, Giovanni Duro, FP907
+HISTORY OF ANDERSON - FABRY DISEASE, ''Nephrology Dialysis Transplantation'', Volume 30, Issue suppl_3, 1 May 2015, Page iii379, <nowiki>https://doi.org/10.1093/ndt/gfv186.08</nowiki>
+{{WikiDoc Help Menu}}
+[2] Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. ''Genet Med'' 2006;8: 539–548.
+[3] Elleder M, Poupĕtová H, Kozich V . Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I. ''Cesk Patol'' 1998;34:7–12.
-[[de:Morbus Fabry]]
+[4] Thurberg BL, Politei JM . Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. ''Hum Pathol'' 2012;43:610–614.
 [[fr:Maladie de Fabry]]
-[[fi:Fabryn tauti]]
+[5] Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M; European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006 Apr;43(4):347-52. Epub 2005 Oct 14. Citation on PubMed or Free article on PubMed Central
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}
 [[Category:Genetic disorders]]